As part of a request for comments on the possibility of the UN designation for cannabidiol (CBD), the US Food and Drug Administration (FDA) has at long last admitted to the medical benefits of CBD on the Federal Register.
In the notice sent by FDA deputy commissioner on Tuesday (August 15), Anna K. Abram recognized the advantages for patients to use CBD properties in combating diseases. “CBD has been shown to be beneficial in experimental models of several neurological disorders, including those of seizure and epilepsy,” the document indicated.
While CBD and cannabis as a whole remain illegal thanks to the Controlled Substances Act (CSA), the drug has seen advances in the US as a number of states have legalized it in some way and look to embrace a commercial model for the drug.


US Election 2020 and Cannabis

 
Investing in cannabis? Read what experts have to say about cannabis and the US Election!
 


On a national level, CBD remains illegal causing a gray area as to what the limits in its use and commercialization are in legal states. Withthe licenses provided by the states, companies supply cannabis for either medical or recreational use. As part of the 1971 Convention on Psychotropic Substances, the UN included tetrahydrocannabinol into its Schedule I designation list
The World Health Organization (WHO) is currently reviewing the status of 17 different substances. As part of this investigation, the FDA will collect input from people willing to share their experiences on “abuse potential, actual abuse, medical usefulness, trafficking, and impact of scheduling changes on availability for medical use,” for several drugs including CBD, until Sept. 13.
Based on the comments the US Department of Health & Human Services (HHS) will prepare an evaluation of the drugs and forward the medical and scientific calculation to WHO, through the Secretary of State.
Even if the FDA obtains an outpour of positive responses from the public, it won’t directly recommend the WHO to change the status of CBD.
“Instead, HHS will defer such consideration until WHO has made official recommendations to the Commission on Narcotic Drugs, which are expected to be made in early 2018,” the document said.

Investor Takeaway

This is an encouraging step for forward for cannabis enthusiasts and investors in companies in the field. However, there is still a long way for CBD to go before there’s any actual change in the rule of the land for the US.
Don’t forget to follow us @INN_Cannabis & @INN_LifeScience for real-time news updates!
Securities Disclosure: I, Bryan Mc Govern, hold no direct investment interest in any company mentioned in this article.


US Election 2020 and Cannabis

 
Investing in cannabis? Read what experts have to say about cannabis and the US Election!
 

The Israeli cannabis market is picking up with a new supply deal from a Canadian producer.

Also this week, new data showed sales of Canadian cannabis edible products may be stalling.

Keep reading... Show less

The Israeli cannabis market is picking up as a Canadian producer announced a new supply deal in the country.

Also this week it was shown the sales of Canadian cannabis edible products may be stalling, according to new data.

Keep reading... Show less

The Portnoy Law Firm advises investors that class action lawsuits have been filed on behalf of investors in the following publicly traded companies. Shareholders interested in taking an active role in these cases have until the deadlines indicated below to petition the court. There is no cost or obligation to you. See below for more information on these cases.

Credit Acceptance Corporation investors (NASDAQ: CACC); December 1, 2020 deadline, click here to join .

Keep reading... Show less
  • On November 19 , the Mexican Senate passed comprehensive adult-use cannabis legalization, moving Mexico towards becoming one of the few countries to legalize cannabis nationally
  • On March 31, 2020 , the Company entered into an agreement with Tecnologico de Monterrey , the leading university in Mexico , to educate physicians across Latin America , in advance of the impending regulations in Mexico
  • To date, close to 550 LatAm physicians have obtained their diploma accrediting completion of Khiron’s medical education program
  • The Company plans to deploy its ZereniaTM medical cannabis clinics and telehealth strategy in Mexico , building on the success of its vertical integration strategy in Colombia
  • Expanding the Zerenia clinic strategy will build on the Company’s Colombia knowledge and proven distribution capabilities, with rapid telehealth service adoption and over 5,600 medical cannabis scripts filled to date
  • Mexico represents one of the largest potential markets for medical cannabis in the world and is anticipated to reach $1.2bn USD by 2028 (Prohibition Partners).
  • Company to release Q3 2020 financials and host webcast on Tuesday, December 1st

Khiron Life Sciences Corp. (“Khiron” or the “Company”) (TSXV: KHRN ), (OTCQX: KHRNF), ( Frankfurt : A2JMZC), a vertically integrated cannabis leader with core operations in Latin America and Europe welcomes the passing of adult-use cannabis legislation by the Mexican Senate, which moves the country closer to a legalized cannabis market, and towards provision for medical cannabis products.  Khiron has had a presence in Mexico since 2018 and has been working with doctors and medical institutions to develop a deep understanding of the market.

Keep reading... Show less

Recap of special management call includes upcoming corporate milestones and details of proposed combination with established beverage manufacturer

Emerging leader in infused cannabis beverages, BevCanna Enterprises Inc. (CSE:BEV, OTCQB:BVNNF, FSE:7BC) (“BevCanna” or the “Company”) is pleased to provide a recorded recap of the special management call held on Tuesday November 24, 2020. The call discussed upcoming corporate milestones and reviewed recent developments at the developer and manufacturer of cannabinoid‐infused beverages and consumer products for in‐house brands and white label clients.

Keep reading... Show less